Inovalon, a leading technology company providing advanced cloud-based analytics and data-driven intervention platforms to the healthcare industry, will present results from two studies related to Medicaid and Medicare Advantage quality performance measurement during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Philadelphia. The studies feature data from Inovalon's Medical Outcomes Research for Effectiveness and Economics  Registry(R), one of the industry's largest healthcare datasets.

Christie Teigland, PhD, Inovalon's senior director of statistical research, will review the study findings during the following sessions:

• Patient, Plan, and Community Factors Associated with Receipt of

Disease-Modifying Antirheumatic Drugs among Patients with Rheumatoid

• Arthritis in Medicare Managed Care Plans, Tuesday, May 19, at 1:15 p.m. This session will review factors associated with effective treatment of patients with rheumatoid arthritis drugs and provide new evidence that health plans can use to identify subgroups of members for improved rheumatoid arthritis management.

• Differences in Breast Cancer Screening Rates in Medicare Advantage

Dual-Eligible Members Enrolled in Special Needs Plans and Other Health

Care Plans Versus Non-Dual-Eligible Members, Wednesday, May 20 at 12:45 p.m. This session examines differences in breast cancer screening rates and the characteristics associated with lower treatment rates including living in a metropolitan area, a primary care shortage area, a poor or lower educated neighborhood, and an institutional setting.

"Inovalon is using advanced analytics to unleash the power of big data to better understand factors related to health disparities in disadvantaged and dual eligible Medicaid and Medicare Advantage beneficiaries," said Ms. Teigland. "These findings can be used by health plans, integrated healthcare delivery systems, and provider organizations to identify groups of members with worse outcomes for targeted data-driven interventions to improve overall clinical and quality outcomes in this vulnerable population. The findings also support improved clinical outcomes, greater utilization cost efficiency, and higher performance on their Medicare Advantage Five Star quality incentive ratings."

These studies were made possible by the combination of Inovalon's big data analytics platform and the Company's MORE2 Registry(R). As of March 2015, Inovalon's MORE2 Registry(R) contained clinical data pertaining to more than 121 million patients, 763,000 physicians, and 257,000 clinical facilities.